Abstract
9543 Treatment of cancer often involves the use of chemotherapeutic agents that preferentially target tumor cells. Doxorubicin is an anthracycline antibiotic that induces an anticancer effect through intercalation into DNA, and inhibition of topoisomerase II. However, not all patients benefit from doxorubicin therapy and heterogeneity in the response to this agent has limited its clinical efficacy. In order to improve the efficiency of doxorubicin in a greater number of patients, we used RNA interference (RNAi) knockdown experiments to determine the extent to which a change in gene expression can increase cellular sensitivity to the anticancer effects of doxorubicin. RNAi is a naturally occurring mechanism that can be experimentally exploited by introducing double-stranded RNA molecules of ∼21 base pairs termed short interfering RNAs (siRNAs) into cells to achieve sequence specific silence of gene expression. We have applied high-throughput RNAi analysis using a library of 83 siRNAs against 40 cancer-asso...
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call